Joshua Shua Haim, MD
Geriatric Medicine · Manchester, NJNPI 1073554879
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,065 of the $44,704 with a category attached, or 67.3%. Otsuka America Pharmaceutical, Inc. accounts for 81.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $22,866 and has fallen 61.6% since, to $8,774 in 2025. Among geriatric medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 448 payments — averaging $99.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$36K
- AbbVie$1K
- GSK$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Grifols Biologicals LLC$747
- Acadia Pharmaceuticals Inc$615
- plus $4K from 25 others
Across 4 payments — averaging $36,884 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Biologicals LLC$132K
- Eli Lilly$16K
- Biogen$231
- Merck$62
What the payments were for
- Speaking & faculty fees$30,06567%
- Travel & lodging$6,24914%
- Food & beverage$7,88818%
- Education$5011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 50 | $36,288 |
| AbbVie(2 entities) | 92 | $1,094 |
| GSK | 65 | $1,051 |
| Teva Pharmaceuticals USA, Inc. | 30 | $1,033 |
| Grifols Biologicals LLC | 4 | $747 |
| Acadia Pharmaceuticals Inc | 18 | $615 |
| Sunovion Pharmaceuticals Inc. | 51 | $565 |
| Johnson & Johnson | 38 | $564 |
| AstraZeneca | 21 | $548 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $403 |
| Astellas Pharma US Inc | 10 | $351 |
| E.r. Squibb & Sons, L.L.C. | 5 | $345 |
| Biogen | 12 | $200 |
| Lilly USA, LLC | 7 | $199 |
| Sanofi | 1 | $150 |
| Boehringer Ingelheim | 6 | $82 |
| Eisai Inc. | 3 | $79 |
| Novo Nordisk | 4 | $61 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 3 | $44 |
| Acorda Therapeutics, Inc | 3 | $41 |
| UCB, Inc. | 2 | $29 |
| Merck | 2 | $28 |
| Alkermes, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$35,888
- Albutein$725
- Flebogamma DIF$725
- Austedo XR$333
- TRELEGY ELLIPTA$235
- ELIQUIS$231
- DUPIXENT$150
- FARXIGA$130
- LOKELMA$130
- ANORO$125
- SPRAVATO$125
- VRAYLAR$122
- KISUNLA$112
- AUSTEDO$103
How this compares
$44,704 in reported general payments places this provider in the 95th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 302 | $908,347 |
| Invega SustennaPaliperidone Palmitate | 64 | $202,918 |
| EliquisApixaban | 469 | $137,911 |
| Avonex (4 Pack)Interferon Beta-1a | 11 | $96,902 |
| NuplazidPimavanserin Tartrate | 27 | $75,194 |
| XareltoRivaroxaban | 175 | $53,380 |
| AptiomEslicarbazepine Acetate | 75 | $53,048 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $53,005 |
| Divalproex Sodium | 866 | $45,382 |
| Breo ElliptaFluticasone/Vilanterol | 104 | $45,369 |
| JanuviaSitagliptin Phosphate | 152 | $43,572 |
| XifaxanRifaximin | 25 | $39,435 |
| FarxigaDapagliflozin Propanediol | 113 | $37,390 |
| TrulicityDulaglutide | 32 | $33,826 |
| Austedo XrDeutetrabenazine | 13 | $31,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,033 | $939,924315 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Procrit | $564 | $273,136255 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,051 | $119,830269 claims |
| BiogenAvonex (4 Pack) | $200 | $96,90211 claims |
| Acadia Pharmaceuticals IncNuplazid | $615 | $75,19427 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $565 | $53,04875 claims |
| AstraZenecaFarxiga, Lokelma | $548 | $46,429141 claims |
| MerckJanuvia | $28 | $43,572152 claims |
| AbbVieLinzess, Vraylar | $1,094 | $37,97553 claims |
| Lilly USA, LLCTrulicity | $199 | $33,82632 claims |
| Boehringer IngelheimJardiance | $82 | $29,54059 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $36,288 | $27,62442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in Manchester
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Theresa RedlingLivingston$7K
- Sarita RastogiHackensack$7K
- Leslie FeiginDenville$7K
- Karambir DalalWhiting$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.